• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为何人们通过数字方式而非亲自就诊来寻求肥胖症治疗:对一家大型非补贴数字肥胖症服务提供商的患者进行的多国民定量分析

Why People Seek Obesity Care Through Digital Rather Than In-Person Services: A Quantitative Multinational Analysis of Patients From a Large Unsubsidized Digital Obesity Provider.

作者信息

Talay Louis A, Vickers Matt

机构信息

Department of Medical Research, Eucalyptus, Sydney, AUS.

Department of Clinical Governance, Eucalyptus, Sydney, AUS.

出版信息

Cureus. 2024 Dec 12;16(12):e75603. doi: 10.7759/cureus.75603. eCollection 2024 Dec.

DOI:10.7759/cureus.75603
PMID:39669645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11637225/
Abstract

Digital modalities have been demonstrated to improve access and adherence to various chronic care services by mitigating geographical, temporal, and psychological barriers to ongoing multidisciplinary consultations, which such diseases necessitate. The net utility of medication-supported digital weight-loss services (DWLSs) has been intensely debated over the past few years due to their rapid uptake against the backdrop of the obesity epidemic. However, research on these services in real-world settings is scarce. Patients of a large multinational DWLS were emailed a four-question survey, soliciting their reasons for using the service instead of face-to-face (F2F) alternatives. Responses were collected from 1,283 patients, including 481 from the United Kingdom, 428 from Germany, and 374 from Australia. Personal discomfort in discussing weight loss in F2F settings was the most common reason for subscribing to the Eucalyptus DWLS across the full cohort ( = 557, 43.41%), followed by the modality's flexibility ( = 441, 34.37%), patient inability to access comprehensive obesity care through a local general practitioner (GP) ( = 435, 33.90%), and marketing or brand awareness ( = 358, 27.90%). Several significant differences were observed between country, gender, ethnicity, and regular GP status across each of the subscription reasons. This study contributed another important layer to the emerging literature on DWLSs by generating preliminary quantitative evidence of their benefits to obesity care access. However, the findings also indicated that a certain number of patients may be subscribing to such services simply to access weight-loss medications rather than multidisciplinary care. To derive clearer conclusions about this concern, follow-up studies should aim to analyze health coaching engagement markers across a range of service providers.

摘要

数字模式已被证明可通过减轻持续多学科会诊的地理、时间和心理障碍,来改善对各种慢性病护理服务的获取和依从性,而这些疾病需要这种多学科会诊。在肥胖症流行的背景下,药物支持的数字减肥服务(DWLS)因其迅速普及,在过去几年中受到了激烈辩论。然而,在现实环境中对这些服务的研究却很少。一家大型跨国DWLS的患者收到了一份包含四个问题的电子邮件调查问卷,询问他们选择使用该服务而非面对面(F2F)替代方式的原因。共收集到1283名患者的回复,其中包括来自英国的481名、德国的428名和澳大利亚的374名。在整个队列中,在面对面环境中讨论减肥时的个人不适感是订阅尤加利ptus DWLS最常见的原因(n = 557,43.41%),其次是该模式的灵活性(n = 441,34.37%)、患者无法通过当地全科医生(GP)获得全面的肥胖症护理(n = 435,33.90%)以及营销或品牌认知度(n = 358,27.90%)。在每个订阅原因方面,观察到国家、性别、种族和是否有固定全科医生之间存在若干显著差异。本研究通过生成关于DWLS对肥胖症护理获取益处的初步定量证据,为关于DWLS的新兴文献增添了重要的一层。然而,研究结果还表明,一定数量的患者可能只是为了获取减肥药物而订阅此类服务,而非多学科护理。为了就这一问题得出更明确的结论,后续研究应旨在分析一系列服务提供商的健康指导参与指标。

相似文献

1
Why People Seek Obesity Care Through Digital Rather Than In-Person Services: A Quantitative Multinational Analysis of Patients From a Large Unsubsidized Digital Obesity Provider.为何人们通过数字方式而非亲自就诊来寻求肥胖症治疗:对一家大型非补贴数字肥胖症服务提供商的患者进行的多国民定量分析
Cureus. 2024 Dec 12;16(12):e75603. doi: 10.7759/cureus.75603. eCollection 2024 Dec.
2
The Utility of a Digital Glucose-Like Peptide-1 Receptor Agonist-Supported Weight-Loss Service in Regional Australia: A Qualitative Analysis of Interviews With Current Patients of the Eucalyptus Program.数字胰高血糖素样肽-1受体激动剂支持的减肥服务在澳大利亚地区的效用:对桉树项目现有患者访谈的定性分析
Aust J Rural Health. 2025 Feb;33(1):e13220. doi: 10.1111/ajr.13220.
3
Patient Adherence to a Real-World Digital, Asynchronous Weight Loss Program in Australia That Combines Behavioural and GLP-1 RA Therapy: A Mixed Methods Study.澳大利亚一项结合行为疗法和GLP-1受体激动剂疗法的真实世界数字异步减肥计划的患者依从性:一项混合方法研究。
Behav Sci (Basel). 2024 Jun 6;14(6):480. doi: 10.3390/bs14060480.
4
The Effect of Lifestyle Coaching Design on Patient Engagement and Weight Loss in Non-diabetic Patients of a Semaglutide-Supported Digital Obesity Program in the UK: A Comparative Retrospective Cohort Study.生活方式指导设计对英国司美格鲁肽支持的数字肥胖项目中非糖尿病患者的患者参与度和体重减轻的影响:一项比较性回顾性队列研究。
Cureus. 2024 Nov 23;16(11):e74321. doi: 10.7759/cureus.74321. eCollection 2024 Nov.
5
The Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Cohort Study.基于应用程序的司美格鲁肽支持的减肥服务中的配药错误率:一项回顾性队列研究。
Pharmacy (Basel). 2024 Sep 3;12(5):135. doi: 10.3390/pharmacy12050135.
6
GLP-1 RA Prescribing Errors in a Multidisciplinary Digital Weight-Loss Service: A Retrospective Quantitative Analysis.多学科数字减肥服务中GLP-1受体激动剂的处方错误:一项回顾性定量分析
Healthcare (Basel). 2024 Oct 21;12(20):2093. doi: 10.3390/healthcare12202093.
7
Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study.数字参与对使用GLP-1和双重GLP-1/GIP受体激动剂疗法的肥胖症患者体重减轻结果的影响:回顾性队列服务评估研究。
J Med Internet Res. 2025 Mar 31;27:e69466. doi: 10.2196/69466.
8
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
9
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.超越黑木树:影响澳大利亚地区、农村和偏远地区的健康研究问题的快速综述。
Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881.
10
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.关于新型基于胰高血糖素样肽-1受体激动剂(GLP-1RA)的减肥疗法的使用、临床及对比疗效和不良反应的真实世界证据。
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.

引用本文的文献

1
ChatGPT-4o and 4o1 Preview as Dietary Support Tools in a Real-World Medicated Obesity Program: A Prospective Comparative Analysis.ChatGPT-4o和4o1预览版作为现实世界药物性肥胖项目中的饮食支持工具:一项前瞻性比较分析。
Healthcare (Basel). 2025 Mar 16;13(6):647. doi: 10.3390/healthcare13060647.

本文引用的文献

1
GLP-1 RA Prescribing Errors in a Multidisciplinary Digital Weight-Loss Service: A Retrospective Quantitative Analysis.多学科数字减肥服务中GLP-1受体激动剂的处方错误:一项回顾性定量分析
Healthcare (Basel). 2024 Oct 21;12(20):2093. doi: 10.3390/healthcare12202093.
2
The Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Cohort Study.基于应用程序的司美格鲁肽支持的减肥服务中的配药错误率:一项回顾性队列研究。
Pharmacy (Basel). 2024 Sep 3;12(5):135. doi: 10.3390/pharmacy12050135.
3
Patient Adherence to a Real-World Digital, Asynchronous Weight Loss Program in Australia That Combines Behavioural and GLP-1 RA Therapy: A Mixed Methods Study.澳大利亚一项结合行为疗法和GLP-1受体激动剂疗法的真实世界数字异步减肥计划的患者依从性:一项混合方法研究。
Behav Sci (Basel). 2024 Jun 6;14(6):480. doi: 10.3390/bs14060480.
4
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球疾病、伤害和危险因素负担研究 2021 年,1990-2021 年全球 204 个国家和地区及 811 个次国家地区 371 种疾病和伤害的发病率、患病率、伤残损失生命年(YLDs)、伤残调整生命年(DALYs)以及健康期望寿命(HALE):系统分析
Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17.
5
Effectiveness and care continuity in an app-based, glucagon-like peptide-1 receptor agonist-supported weight-loss service for women with overweight and obesity in the UK: A real-world retrospective cohort analysis.英国一项基于应用程序、以胰高血糖素样肽-1受体激动剂为支持的超重和肥胖女性减肥服务的有效性及护理连续性:一项真实世界回顾性队列分析
Diabetes Obes Metab. 2024 Jul;26(7):2984-2987. doi: 10.1111/dom.15607. Epub 2024 Apr 16.
6
Direct-to-Consumer Platforms for New Antiobesity Medications - Concerns and Potential Opportunities.新型抗肥胖药物的直接面向消费者的平台——担忧与潜在机遇
N Engl J Med. 2024 Feb 22;390(8):677-680. doi: 10.1056/NEJMp2312816. Epub 2024 Feb 17.
7
Assessing Patient Adherence to and Engagement With Digital Interventions for Depression in Clinical Trials: Systematic Literature Review.评估临床试验中抑郁症数字干预措施的患者依从性和参与度:系统文献回顾。
J Med Internet Res. 2023 Aug 11;25:e43727. doi: 10.2196/43727.
8
Editorial: Environmental factors implicated in obesity.社论:与肥胖相关的环境因素。
Front Nutr. 2023 May 4;10:1171507. doi: 10.3389/fnut.2023.1171507. eCollection 2023.
9
Digital Health Solutions for Weight Loss and Obesity: A Narrative Review.数字健康解决方案在减肥和肥胖管理中的应用:叙事性综述。
Nutrients. 2023 Apr 12;15(8):1858. doi: 10.3390/nu15081858.
10
Association between socio-economic factors and the risk of overweight and obesity among Chinese adults: a retrospective cross-sectional study from the China Health and Nutrition Survey.社会经济因素与中国成年人超重和肥胖风险的关联:来自中国健康与营养调查的回顾性横断面研究。
Glob Health Res Policy. 2022 Oct 31;7(1):41. doi: 10.1186/s41256-022-00274-y.